Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-09-30

Study Completion Date

2009-08-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to compare four currently used types of anesthesia used prior to intravitreal injection in order to evaluate the most effective method of anesthesia in reducing pain and discomfort associated with intravitreal injections.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Oral Sedation in Vitreoretinal Surgery

NCT04346095

Macular Holes Intraocular Lens Opacification Vitrectomy +5 more

UNKNOWN PHASE4

Comparison of Three Different Anesthetic Approaches for Intravitreal Injections

NCT02263690

Pain

COMPLETED PHASE4

Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections

NCT02951351

COMPLETED NA

Patient Assessment of Topical Anesthetic Effectiveness for Intravitreal Injections

NCT01027611

Pain

COMPLETED PHASE3

Comparison of Patient Comfort After Two Anesthetic Protocols for Injections Into the Eye

NCT01087489

Pain

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Over the last several years intravitreal injection of pharmacologic agents has become a common procedure in ophthalmology. Injected agents include steroid, antibiotics, and most recently anti-VEGF agents. There are many methods of preparing a patient for intravitreal injection. While there are guidelines for infection prophylaxis, there is currently no standard of care or consensus on which method of anesthesia is most effective in reducing pain and discomfort associated with intravitreal injections.

Patients who have received prior injections and are scheduled to continue regular injections will be randomized to utilize one of four types of anesthetic treatment for each of 4 treatment periods,so that each subject receives all four types of anesthesia over the course of the study. The order of the anesthetic treatment the subject will receive prior to each planned intravitreal injection during the study period will be different for each subject. This will decrease the effect of extraneous variables from influencing subjective pain scores.

Following each procedure, patients will fill out an analog pain scale questionnaire, grading the discomfort of receiving both the anesthesia and the injection(on separate 0-10 scales).

The anesthetic methods used will include: 1.) Drops of Proparacaine on the eye, 2.) Drops of Tetracaine on the eye, 3.) A cotton sponge (pledget) soaked with Lidocaine 4% placed over the conjunctiva and 4.)A subconjunctival injection with 2% Lidocaine.

The subjects' number and type of visits, tests and treatments will be standard of care and will not be different due to the study. The total time for the treatment part of the study coincides with four injections (1 injection per month) or approximately 4 months and will be followed for up to 6 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Macular Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Intervention Model

SEQUENTIAL

Participants will be randomized to receive a unique sequence of one of the 4 anesthetic agents per month, prior to a standard of care monthly intravitreal injection (1 injection per month for a total of 4 months). At the end of study participation, each patient will have received each of the 4 anesthetic agents once prior to one of the 4 intravitreal injections (ex. Randomization to sequence: Proparcacaine used prior to Injection 1; Tetracaine used prior to Injection 2; Lidocaine sponge used prior to Injection 3; Lidocaine suconjunctival injection used prior to Injection 4).

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All Participants

All Participants will be randomized to receive a unique sequence of one of the 4 anesthetic agents per month, prior to a standard of care monthly intravitreal injection (1 injection per month for a total of 4 months). At the end of study participation, each patient will have received each of the 4 anesthetic agents once prior to one of the 4 intravitreal injections (ex. Randomization to sequence: Proparacaine Ophthalmic drops used prior to Injection 1; Tetracaine Ophthalmic drops used prior to Injection 2; Lidocaine 4% sponge used prior to Injection 3; Lidocaine 2% injectable solution (subconjunctival) used prior to Injection 4).

Group Type OTHER

Proparacaine Ophthalmic

Intervention Type DRUG

Drops of Proparacaine on the eye, administered as described in the package insert

Tetracaine Ophthalmic

Intervention Type DRUG

Drops of Tetracaine on the eye, administered as described in the package insert

Lidocaine 4%

Intervention Type DRUG

A cotton sponge(pledget)soaked with Lidocaine 4% placed over the conjunctiva

Lidocaine 2% Injectable Solution

Intervention Type DRUG

A subconjunctival injection of Lidocaine 2%

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Proparacaine Ophthalmic

Drops of Proparacaine on the eye, administered as described in the package insert

Intervention Type DRUG

Tetracaine Ophthalmic

Drops of Tetracaine on the eye, administered as described in the package insert

Intervention Type DRUG

Lidocaine 4%

A cotton sponge(pledget)soaked with Lidocaine 4% placed over the conjunctiva

Intervention Type DRUG

Lidocaine 2% Injectable Solution

A subconjunctival injection of Lidocaine 2%

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female \> 40 years of age
* Diagnosis of age-related macular degeneration
* History of at least 1 intravitreal injection in the past in either eye
* Written informed consent has been obtained